Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Gabriella Parma

Showing results (11-20 of 28) with videos related to

Pageof 3
Sort By:
Cancers|January 11, 2024
A Ten-Year Real-Life Experience with Pazopanib in Uterine Leyomiosarcoma in Two High-Specialized Centers in Italy: Effectiveness and SafetyMara Mantiero, Marta Bini, Maggie Polignano, et al.
International Journal of Radiation Oncology, Biology, Physics|June 13, 2018
Stereotactic Body Radiation Therapy for Oligometastatic Ovarian Cancer: A Step Toward a Drug HolidayRoberta Lazzari, Sara Ronchi, Sara Gandini, et al.
International Journal of Cancer|August 29, 2020
Clinical presentation, diagnosis and management of therapy-related hematological disorders in women with epithelial ovarian cancer treated with chemotherapy and poly-ADP-ribose polymerase inhibitors: A single-center experienceElisabetta Todisco, Federica Gigli, Mara Mantiero, et al.
Anticancer Research|September 6, 2017
Risk-reducing Salpingo-Oophorectomy in Women at Higher Risk of Ovarian and Breast Cancer: A Single Institution Prospective SeriesEnzo Ricciardi, Federica Tomao, Giovanni Aletti, et al.
International Journal of Cancer|June 13, 2022
Hematological disorders after salvage PARPi treatment for ovarian cancer: Cytogenetic and molecular defects and clinical outcomesElisabetta Todisco, Federica Gigli, Chiara Ronchini, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|May 29, 2012
An open-label phase 2 study of twice-weekly bortezomib and intermittent pegylated liposomal doxorubicin in patients with ovarian cancer failing platinum-containing regimensGabriella Parma, Rosanna Mancari, Gianluca Del Conte, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|November 10, 2023
Dose-dense neoadjuvant chemotherapy before radical surgery in cervical cancer: a retrospective cohort study and systematic literature reviewGiuseppe Caruso, Simone Bruni, Mariateresa Lapresa, et al.
Gynecologic Oncology|February 9, 2025
Rechallenge with platinum-based chemotherapy in patients with platinum-resistant ovarian carcinoma: A cohort studyCarmine Valenza, Marta Mongillo, Maria Vittoria Visconti, et al.
The Oncologist|November 28, 2024
Germline BRCA pathogenic variants and hematologic adverse events in patients with ovarian carcinoma receiving PARP inhibitors: a retrospective cohort studyCarmine Valenza, Eleonora Nicolò, Marta Mongillo, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|February 9, 2023
Adult ovarian granulosa cell tumors: analysis of outcomes and risk factors for recurrenceHelmut Plett, Enzo Ricciardi, Vlad Vacaru, et al.
Pageof 3

Showing results (11-20 of 28) with videos related to

Sort By:
Pageof 3
Cancers|January 11, 2024
A Ten-Year Real-Life Experience with Pazopanib in Uterine Leyomiosarcoma in Two High-Specialized Centers in Italy: Effectiveness and SafetyMara Mantiero, Marta Bini, Maggie Polignano, et al.
International Journal of Radiation Oncology, Biology, Physics|June 13, 2018
Stereotactic Body Radiation Therapy for Oligometastatic Ovarian Cancer: A Step Toward a Drug HolidayRoberta Lazzari, Sara Ronchi, Sara Gandini, et al.
International Journal of Cancer|August 29, 2020
Clinical presentation, diagnosis and management of therapy-related hematological disorders in women with epithelial ovarian cancer treated with chemotherapy and poly-ADP-ribose polymerase inhibitors: A single-center experienceElisabetta Todisco, Federica Gigli, Mara Mantiero, et al.
Anticancer Research|September 6, 2017
Risk-reducing Salpingo-Oophorectomy in Women at Higher Risk of Ovarian and Breast Cancer: A Single Institution Prospective SeriesEnzo Ricciardi, Federica Tomao, Giovanni Aletti, et al.
International Journal of Cancer|June 13, 2022
Hematological disorders after salvage PARPi treatment for ovarian cancer: Cytogenetic and molecular defects and clinical outcomesElisabetta Todisco, Federica Gigli, Chiara Ronchini, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|May 29, 2012
An open-label phase 2 study of twice-weekly bortezomib and intermittent pegylated liposomal doxorubicin in patients with ovarian cancer failing platinum-containing regimensGabriella Parma, Rosanna Mancari, Gianluca Del Conte, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|November 10, 2023
Dose-dense neoadjuvant chemotherapy before radical surgery in cervical cancer: a retrospective cohort study and systematic literature reviewGiuseppe Caruso, Simone Bruni, Mariateresa Lapresa, et al.
Gynecologic Oncology|February 9, 2025
Rechallenge with platinum-based chemotherapy in patients with platinum-resistant ovarian carcinoma: A cohort studyCarmine Valenza, Marta Mongillo, Maria Vittoria Visconti, et al.
The Oncologist|November 28, 2024
Germline BRCA pathogenic variants and hematologic adverse events in patients with ovarian carcinoma receiving PARP inhibitors: a retrospective cohort studyCarmine Valenza, Eleonora Nicolò, Marta Mongillo, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|February 9, 2023
Adult ovarian granulosa cell tumors: analysis of outcomes and risk factors for recurrenceHelmut Plett, Enzo Ricciardi, Vlad Vacaru, et al.
Pageof 3